• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫颈癌全身治疗的格局变迁:抑制转化生长因子-β(TGF-β)和程序性死亡配体1(PD-L1)通路的理论依据

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways.

作者信息

Birrer Michael J, Fujiwara Keiichi, Oaknin Ana, Randall Leslie, Ojalvo Laureen S, Valencia Christian, Ray-Coquard Isabelle

机构信息

Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, United States.

Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

出版信息

Front Oncol. 2022 Feb 23;12:814169. doi: 10.3389/fonc.2022.814169. eCollection 2022.

DOI:10.3389/fonc.2022.814169
PMID:35280818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8905681/
Abstract

Cervical cancer is one of the most common and lethal cancers among women worldwide. Treatment options are limited in patients with persistent, recurrent, or metastatic cervical cancer, with <20% of women living >5 years. Persistent human papillomavirus (HPV) infection has been implicated in almost all cases of cervical cancer. HPV infection not only causes normal cervical cells to transform into cancer cells, but also creates an immunosuppressive environment for cancer cells to evade the immune system. Recent clinical trials of drugs targeting the PD-(L)1 pathway have demonstrated improvement in overall survival in patients with cervical cancer, but only 20% to 30% of patients show overall survival benefit beyond 2 years, and resistance to these treatments remains common. Therefore, novel treatment strategies targeting HPV infection-associated factors are currently being evaluated in clinical trials. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β "trap") fused to a human immunoglobulin G1 monoclonal antibody that blocks PD-L1. Early clinical trials of bintrafusp alfa have shown promising results in patients with advanced cervical cancer.

摘要

宫颈癌是全球女性中最常见且致命的癌症之一。对于持续性、复发性或转移性宫颈癌患者,治疗选择有限,只有不到20%的女性存活超过5年。几乎所有宫颈癌病例都与持续性人乳头瘤病毒(HPV)感染有关。HPV感染不仅会使正常宫颈细胞转变为癌细胞,还会为癌细胞创造一个免疫抑制环境以逃避免疫系统。近期针对PD-(L)1通路的药物临床试验表明,宫颈癌患者的总生存期有所改善,但只有20%至30%的患者在2年以上显示出总生存期获益,并且对这些治疗的耐药性仍然很常见。因此,目前正在临床试验中评估针对HPV感染相关因素的新型治疗策略。Bintrafusp alfa是一种一流的双功能融合蛋白,由TGF-βRII受体的细胞外结构域(一种TGF-β“陷阱”)与阻断PD-L1的人免疫球蛋白G1单克隆抗体融合而成。Bintrafusp alfa的早期临床试验在晚期宫颈癌患者中显示出了有前景的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b7/8905681/8169062d97db/fonc-12-814169-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b7/8905681/b92d8061d32b/fonc-12-814169-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b7/8905681/8169062d97db/fonc-12-814169-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b7/8905681/b92d8061d32b/fonc-12-814169-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37b7/8905681/8169062d97db/fonc-12-814169-g002.jpg

相似文献

1
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways.宫颈癌全身治疗的格局变迁:抑制转化生长因子-β(TGF-β)和程序性死亡配体1(PD-L1)通路的理论依据
Front Oncol. 2022 Feb 23;12:814169. doi: 10.3389/fonc.2022.814169. eCollection 2022.
2
Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.双重抑制 TGF-β 和 PD-L1:一种新的癌症治疗方法。
Mol Oncol. 2022 Jun;16(11):2117-2134. doi: 10.1002/1878-0261.13146. Epub 2022 Jan 4.
3
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.双功能融合蛋白靶向 TGF-β 和 PD-L1 的 Bintrafusp alfa 在人乳头瘤病毒相关恶性肿瘤患者中的应用。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001395.
4
Radiolabelling and preclinical characterization of Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.Zr-Df 标记的双特异性抗 PD-L1/TGF-βRII 融合蛋白 bintrafusp alfa 的放射性标记及临床前特征。
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3075-3088. doi: 10.1007/s00259-021-05251-0. Epub 2021 Feb 19.
5
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.双功能抗 PD-L1/TGFβRII 药物 Bintrafusp Alfa 的临床前和临床研究:现状。
Exp Biol Med (Maywood). 2022 Jul;247(13):1124-1134. doi: 10.1177/15353702221089910. Epub 2022 Apr 27.
6
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.双功能融合蛋白 Bintrafusp Alfa 靶向 TGF-β 和 PD-L1,治疗食管腺癌患者:来自 1 期队列的结果。
Target Oncol. 2021 Jul;16(4):435-446. doi: 10.1007/s11523-021-00809-2. Epub 2021 May 19.
7
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.分析双功能药物 bintrafusp alfa 皮下给药与系统给药的肿瘤微环境和抗肿瘤疗效。
Oncoimmunology. 2021 May 3;10(1):1915561. doi: 10.1080/2162402X.2021.1915561.
8
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.Bintrafusp Alfa 一线治疗局部晚期或持续性/复发性/转移性宫颈癌的 I 期临床试验。
Clin Cancer Res. 2024 Mar 1;30(5):975-983. doi: 10.1158/1078-0432.CCR-23-1829.
9
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.双靶 TGF-β 和 PD-L1 的双功能抗 PD-L1/TGF-βRII 制剂:临床前和临床进展现状。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000433.
10
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.Bintrafusp Alfa 双功能融合蛋白在亚洲晚期实体瘤患者中的 I 期研究,包括一个肝细胞癌安全性评估队列。
Oncologist. 2020 Sep;25(9):e1292-e1302. doi: 10.1634/theoncologist.2020-0249. Epub 2020 Apr 23.

引用本文的文献

1
Recurrent pembrolizumab-induced mechanical small bowel obstruction in a patient with metastatic cervical cancer.一名转移性宫颈癌患者出现帕博利珠单抗诱发的复发性机械性小肠梗阻。
Gynecol Oncol Rep. 2024 Mar 29;53:101382. doi: 10.1016/j.gore.2024.101382. eCollection 2024 Jun.
2
Adenosine Increases the Immunosuppressive Capacity of Cervical Cancer Cells by Increasing PD-L1 Expression and TGF-β Production through Its Interaction with AR/AR.腺苷通过与AR/AR相互作用增加PD-L1表达和TGF-β产生,从而增强宫颈癌细胞的免疫抑制能力。
Pharmaceuticals (Basel). 2024 Mar 19;17(3):397. doi: 10.3390/ph17030397.
3
Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study.

本文引用的文献

1
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.巴替利单抗和泽利鲁单抗联合双 PD-1 和 CTLA-4 检查点阻断作为晚期宫颈癌二线治疗的开放标签 II 期研究。
J Clin Oncol. 2022 Mar 1;40(7):762-771. doi: 10.1200/JCO.21.02067. Epub 2021 Dec 21.
2
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.高转化生长因子-β特征预示接受免疫检查点抑制治疗的妇科癌症患者的免疫治疗耐药性。
NPJ Precis Oncol. 2021 Dec 17;5(1):101. doi: 10.1038/s41698-021-00242-8.
3
针对 HPV 阳性口咽鳞状细胞癌患者的 HPV L1 抗体亚类 IgA、IgM 和 IgG 的检测:一项初步研究。
Eur Arch Otorhinolaryngol. 2024 May;281(5):2637-2644. doi: 10.1007/s00405-024-08537-9. Epub 2024 Mar 5.
4
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.Bintrafusp Alfa 一线治疗局部晚期或持续性/复发性/转移性宫颈癌的 I 期临床试验。
Clin Cancer Res. 2024 Mar 1;30(5):975-983. doi: 10.1158/1078-0432.CCR-23-1829.
5
Effects of metalloprotease ADAMTS12 on cervical cancer cell phenotype and its potential mechanism.金属蛋白酶ADAMTS12对宫颈癌细胞表型的影响及其潜在机制。
Discov Oncol. 2023 Aug 29;14(1):162. doi: 10.1007/s12672-023-00776-2.
6
Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas.宫颈腺癌中低转化生长因子-β信号通路活性
Front Oncol. 2022 Jun 8;12:797453. doi: 10.3389/fonc.2022.797453. eCollection 2022.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
派姆单抗治疗持续性、复发性或转移性宫颈癌。
N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18.
4
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.抗 PD-1 抗体巴替利单抗治疗复发性和/或转移性宫颈癌患者的安全性和有效性的 II 期研究。
Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25.
5
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times.癌症的细胞毒性化疗与免疫疗法联合应用:现代进展
NAR Cancer. 2020 Feb 17;2(1):zcaa002. doi: 10.1093/narcan/zcaa002. eCollection 2020 Mar.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.双功能融合蛋白靶向 TGF-β 和 PD-L1 的 Bintrafusp alfa 在人乳头瘤病毒相关恶性肿瘤患者中的应用。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001395.
8
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌(CLAP)的多中心、开放标签、单臂、Ⅱ期临床试验。
J Clin Oncol. 2020 Dec 1;38(34):4095-4106. doi: 10.1200/JCO.20.01920. Epub 2020 Oct 14.
9
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.阿替利珠单抗联合贝伐珠单抗治疗晚期宫颈癌的 II 期研究。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001126.
10
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.CECILIA 研究的主要结果,这是一项全球性的单臂 II 期研究,评估贝伐珠单抗、卡铂和紫杉醇治疗晚期宫颈癌。
Gynecol Oncol. 2020 Oct;159(1):142-149. doi: 10.1016/j.ygyno.2020.07.026. Epub 2020 Aug 4.